• Ultragenyx held its annual shareholder meeting on May 14, 2026.
• Shareholders adopted the Third Amended and Restated 2023 Incentive Plan.
• Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228639), on May 18, 2026, and is solely responsible for the information contained therein.